CureLab Oncology
生物技术研究
Boston，Massachusetts 498 位关注者
Revolutionary therapies that prolong lives.
关于我们
CureLab Oncology is a biotechnology company developing new anti-cancer biologics. CureLab Oncology is committed to creating a family of revolutionary therapies for oncology patients in order to help prolong their lives. CureLab Oncology's lead product, Elenagen?, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen? reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor. The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen?. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.
- 网站
-
https://www.curelaboncology.com
CureLab Oncology的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2000
地点
-
主要
获取路线
US，Massachusetts，Boston，02138
CureLab Oncology员工
-
Ilya Lapshin
Intellectual Property; Attorney and Principal at IRL Legal Services, LLC; General Counsel at CureLab Oncology, Inc.
-
Charles Legg
Global Chairman of the Advisory Board, HealthPals | COO CureLab | Remote Home Check Advisor
-
Yuriy Oreshin
Managing General Partner at X Private Equity
-
Marina Kasaikina, Ph.D.
Senior Consultant at Foresight Science & Technology
动态
-
A good analytical piece about cancer vaccines for non-vaccinologists (the only weаk element of the paper is my interview??). I think, a pretty comprehensive and objective article. https://lnkd.in/ejeWRnak
-
CureLab Oncology Secures Patent Protection in Canada for Elenagen, Its P62 Plasmid Cancer Therapeutic https://lnkd.in/eVqk2S67